Sun Pharma recalls over 2,500 bottles of diabetes drug from US

The US arm of Sun Pharmaceutical Industries is recalling over 2,500 bottles of Metformin hydrochloride extended release tablets from Arizona on account of presence of foreign substance in one lot. United States Food and Drug Administration (USFDA) said the company is recalling 2,508 bottles of Metformin hydrochloride extended release tablets 500 mg, packaged in a 500-count bottle.

The reason for recall is presence of foreign substance- one lot of these tablets contains foreign matter identified as a piece of rubber glove detected in one tablet, it added.

The tablets were manufactured at Sun Pharma’s Halol facility, USFDA said in its Enforcement report.

The ongoing, voluntary recall is a class II recall, it added.

As per USFDA, a class II recall is initiated in a situation “in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

Metformin hydrochloride extended release tablets are used to improve glycemic control in adults with type 2 diabetes.

  • Related Posts

    • Pharma
    • July 10, 2025
    • 100 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    • Pharma
    • July 10, 2025
    • 95 views
    Novartis wins approval for first malaria drug for newborns and babies

    ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr